GlassScriptPhysician profile
Donald B Muir
NPI 1245229525
$5,946.03
in general payments reported to CMS, 2019-2025
31 companies · $741 in 2025
The $741 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,269 · 2020: $520 · 2021: $549 · 2022: $704 · 2023: $1,091 · 2024: $1,072 · 2025: $741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,903.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $985.81 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $709.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $707.79 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $593.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $455.01 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $313.73 | 2019-2025 | Breztri, Airsupra |
| Abbvie INC. | $284.99 | 2021-2025 | |
| Glaxosmithkline, LLC. | $279.07 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Exact Sciences Corporation | $265.90 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $213.98 | 2019-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $165.30 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.79 | 2019-2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $129.17 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $86.70 | 2019-2023 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.92 | 2024-2025 | Caplyta |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $62.51 | 2019-2023 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $61.97 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.35 | 2022-2023 | |
| Abbott Laboratories | $56.95 | 2021-2024 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $49.19 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $45.84 | 2021 | |
| Grifols USA, LLC | $36.00 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $29.00 | 2019 | |
| Tactile Systems Technology INC | $24.28 | 2025 | Flexitouch Plus, Nimbl |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.61 | 2023 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $19.18 | 2022 | |
| Bausch Health US, LLC | $18.55 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.28 | 2019 | |
| Radius Health, INC. | $12.26 | 2019 | |
| Allergan, INC. | $11.93 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Muir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.